RxDoctor Payments Data

Nancy Roe

Family · Tifton, GANPI 1124680673

Payments from drug & device makers

$6,327in general payments, 2019–2025

Across 288 payments — averaging $21.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$680
  • Madrigal Pharmaceuticals$531
  • Takeda Pharmaceuticals U.S.A., Inc.$413
  • Ardelyx, Inc.$305
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$262
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$6,20498%
  • Education$1232%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,327 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$70,672
Medicare patients
466
Services billed
736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab17$517,731
Humira(Cf) PenAdalimumab23$158,402
LinzessLinaclotide176$148,050
CreonLipase/Protease/Amylase51$115,138
TrulancePlecanatide19$23,276
IbsrelaTenapanor Hcl13$22,910
Mesalamine33$13,792
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates187$12,104
Dexlansoprazole DrDexlansoprazole51$11,430
Lubiprostone108$10,371
MovantikNaloxegol Oxalate11$7,996
Rabeprazole Sodium124$6,516
DexilantDexlansoprazole15$6,502
Pantoprazole Sodium480$5,333
SutabSod Sulf/Pot Chloride/Mag Sulf32$5,257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$680$517,73117 claims
AbbVieLinzess, Creon$2,551$263,187227 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$262$23,27619 claims
Ardelyx, Inc.Ibsrela$305$22,91013 claims
Redhill Biopharma Inc.Movantik$36$7,99611 claims
Braintree Laboratories, Inc.Sutab, Suflave$149$6,78644 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$413$6,50215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Tifton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →